PriceTargets.com logo

Glaukos - GKOS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $156.17
  • Forecasted Upside: 66.83%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 1 Strong Buy Ratings
$93.61 As of 04/29/2025 04:59 PM ET
▼ -0.201 (-0.21%)

This chart shows the closing price for GKOS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Glaukos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GKOS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GKOS

Analyst Price Target is $156.17
▲ +66.83% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Glaukos in the last 3 months. The average price target is $156.17, with a high forecast of $182.00 and a low forecast of $120.00. The average price target represents a 66.83% upside from the last price of $93.61.

This chart shows the closing price for GKOS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Glaukos. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/5/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/5/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/3/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2024
  • 1 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/30/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/31/2025
  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/30/2025

Latest Recommendations

  • 1 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/16/2025MizuhoLower TargetOutperform ➝ Outperform$200.00 ➝ $175.00
4/15/2025Piper SandlerLower TargetOverweight ➝ Overweight$180.00 ➝ $165.00
4/11/2025Truist FinancialLower TargetBuy ➝ Buy$185.00 ➝ $140.00
2/21/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$153.00 ➝ $160.00
2/21/2025Needham & Company LLCBoost TargetBuy ➝ Buy$149.00 ➝ $176.00
2/19/2025MizuhoUpgradeNeutral ➝ Outperform$140.00 ➝ $200.00
1/27/2025Piper SandlerReiterated RatingOverweight ➝ Overweight$140.00 ➝ $180.00
12/31/2024Stifel NicolausBoost TargetBuy ➝ Buy$153.00 ➝ $175.00
12/18/2024Truist FinancialBoost TargetBuy ➝ Buy$152.00 ➝ $185.00
12/11/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$145.00 ➝ $153.00
12/11/2024CitigroupUpgradeNeutral ➝ Buy$132.00 ➝ $162.00
12/6/2024UBS GroupInitiated CoverageBuy$182.00
12/2/2024StephensUpgradeStrong-Buy
12/2/2024Stifel NicolausBoost TargetBuy ➝ Buy$145.00 ➝ $153.00
12/2/2024Morgan StanleyDowngradeEqual Weight ➝ Underweight$120.00
11/26/2024BTIG ResearchBoost TargetBuy ➝ Buy$140.00 ➝ $149.00
11/5/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$130.00 ➝ $145.00
11/5/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$135.00 ➝ $145.00
10/17/2024Piper SandlerSet Target$140.00
10/14/2024Truist FinancialBoost TargetBuy ➝ Buy$145.00 ➝ $152.00
9/3/2024Stifel NicolausBoost TargetBuy ➝ Buy$130.00 ➝ $145.00
8/28/2024BTIG ResearchBoost TargetBuy ➝ Buy$131.00 ➝ $139.00
8/1/2024Piper SandlerBoost TargetOverweight ➝ Overweight$110.00 ➝ $140.00
8/1/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$120.00 ➝ $135.00
8/1/2024Truist FinancialReiterated RatingBuy ➝ Buy$141.00 ➝ $145.00
8/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$131.00 ➝ $137.00
7/16/2024Truist FinancialBoost TargetBuy ➝ Buy$125.00 ➝ $141.00
7/15/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$100.00 ➝ $120.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$112.00 ➝ $131.00
7/10/2024CitigroupDowngradeBuy ➝ Neutral$130.00 ➝ $132.00
6/5/2024Stifel NicolausBoost TargetBuy ➝ Buy$110.00 ➝ $130.00
6/3/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$110.00 ➝ $120.00
5/22/2024CitigroupBoost TargetBuy ➝ Buy$120.00 ➝ $130.00
5/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$84.00 ➝ $125.00
5/2/2024BTIG ResearchBoost TargetBuy ➝ Buy$107.00 ➝ $112.00
5/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$108.00 ➝ $110.00
5/2/2024Truist FinancialReiterated RatingBuy ➝ Buy$120.00 ➝ $125.00
5/2/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$103.00 ➝ $110.00
5/2/2024Needham & Company LLCBoost TargetBuy ➝ Buy$108.00 ➝ $113.00
4/11/2024MizuhoBoost TargetNeutral ➝ Neutral$85.00 ➝ $100.00
4/8/2024Truist FinancialReiterated RatingBuy ➝ Buy$110.00
4/3/2024Stifel NicolausReiterated RatingBuy ➝ Buy$110.00
3/25/2024CitigroupBoost TargetBuy ➝ Buy$107.00 ➝ $120.00
3/22/2024Truist FinancialReiterated RatingBuy ➝ Buy$110.00
2/22/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$83.00 ➝ $103.00
2/22/2024Needham & Company LLCBoost TargetBuy ➝ Buy$105.00 ➝ $108.00
2/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00
12/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$100.00
12/22/2023Piper SandlerBoost TargetOverweight ➝ Overweight$90.00 ➝ $105.00
12/22/2023Truist FinancialBoost TargetBuy ➝ Buy$88.00 ➝ $100.00
12/21/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$66.00 ➝ $91.00
12/4/2023Morgan StanleyInitiated CoverageEqual Weight$65.00
11/28/2023Truist FinancialInitiated CoverageBuy$88.00
11/8/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$75.00 ➝ $83.00
11/2/2023Needham & Company LLCLower TargetBuy ➝ Buy$89.00 ➝ $83.00
11/2/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$71.00 ➝ $66.00
9/26/2023Stifel NicolausReiterated RatingBuy ➝ Buy$90.00
8/3/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$89.00
8/3/2023BTIG ResearchBoost Target$83.00 ➝ $86.00
8/3/2023MizuhoBoost TargetNeutral ➝ Neutral$80.00 ➝ $85.00
7/31/2023Piper SandlerBoost TargetOverweight ➝ Overweight$80.00 ➝ $85.00
7/17/2023BTIG ResearchBoost Target$67.00 ➝ $83.00
7/17/2023MizuhoBoost Target$52.00 ➝ $80.00
7/14/2023Wells Fargo & CompanyBoost TargetEqual Weight$63.00 ➝ $75.00
7/10/2023CitigroupBoost Target$59.00 ➝ $85.00
6/26/2023Stifel NicolausBoost Target$65.00 ➝ $77.00
6/7/2023Piper SandlerUpgradeNeutral ➝ Overweight$55.00 ➝ $80.00
6/5/2023BTIG ResearchBoost Target$58.00 ➝ $67.00
6/5/2023Wells Fargo & CompanyBoost Target$44.00 ➝ $63.00
5/4/2023888Reiterated RatingMaintains
5/4/2023Needham & Company LLCBoost Target$57.00 ➝ $58.00
4/18/2023MizuhoBoost Target$48.00 ➝ $52.00
2/23/2023JPMorgan Chase & Co.Boost TargetNeutral$42.00 ➝ $48.00
2/23/2023Needham & Company LLCLower TargetBuy$58.00 ➝ $57.00
2/23/2023CitigroupBoost TargetBuy$57.00 ➝ $59.00
2/22/2023William BlairReiterated RatingOutperform
12/28/2022StephensLower TargetOverweight$69.00 ➝ $68.00
12/22/2022MizuhoInitiated CoverageNeutral$48.00
12/19/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$48.00 ➝ $42.00
12/12/2022Wells Fargo & CompanyLower TargetEqual Weight$56.00 ➝ $44.00
12/12/2022CitigroupUpgradeNeutral ➝ Buy$57.00
11/3/2022JPMorgan Chase & Co.Lower TargetUnderweight$52.00 ➝ $48.00
11/3/2022Piper SandlerBoost TargetNeutral$55.00 ➝ $60.00
11/3/2022Needham & Company LLCLower TargetBuy$66.00 ➝ $65.00
10/13/2022StephensInitiated CoverageOverweight$69.00
10/5/2022CitigroupBoost Target$54.00 ➝ $57.00
10/4/2022Needham & Company LLCInitiated CoverageBuy$66.00
8/4/2022CitigroupBoost Target$49.00 ➝ $54.00
7/12/2022Stifel NicolausUpgradeHold ➝ Buy$40.00 ➝ $60.00
5/17/2022CitigroupLower TargetNeutral$58.00 ➝ $43.00
4/18/2022BTIG ResearchBoost Target$61.00 ➝ $66.00
2/23/2022CitigroupBoost TargetNeutral$49.00 ➝ $55.00
2/3/2022William BlairUpgradeMarket Perform ➝ Outperform
1/19/2022Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$56.00
1/18/2022BTIG ResearchUpgradeNeutral ➝ Buy$61.00
1/7/2022William BlairReiterated RatingMarket Perform
11/5/2021Jefferies Financial GroupBoost TargetHold$54.00 ➝ $60.00
11/5/2021Piper SandlerBoost TargetNeutral$45.00 ➝ $55.00
11/3/2021StephensUpgradeEqual Weight ➝ Overweight$60.00 ➝ $68.00
10/14/2021JPMorgan Chase & Co.Lower TargetUnderweight$50.00 ➝ $40.00
8/6/2021StephensLower TargetEqual Weight$70.00 ➝ $60.00
8/6/2021Piper SandlerLower TargetNeutral$80.00 ➝ $45.00
7/28/2021CitigroupLower TargetNeutral$94.00 ➝ $52.00
7/26/2021StephensDowngradeOverweight ➝ Equal Weight$70.00
7/20/2021Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$41.00
7/14/2021OppenheimerDowngradeOutperform ➝ Market Perform$105.00
7/14/2021William BlairDowngradeOutperform ➝ Market Perform$34.00
5/6/2021OppenheimerBoost Target$100.00 ➝ $105.00
4/8/2021OppenheimerUpgradeMarket Perform ➝ Outperform$93.00 ➝ $100.00
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$70.00 ➝ $80.00
12/16/2020Smith Barney CitigroupUpgradeSell ➝ Neutral$50.00 ➝ $72.00
12/8/2020OppenheimerInitiated CoverageMarket Perform$73.00
11/17/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$68.00
11/6/2020Piper SandlerBoost TargetOverweight$60.00 ➝ $70.00
10/8/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$50.00
8/7/2020Piper SandlerBoost TargetPositive ➝ Overweight$50.00 ➝ $60.00
6/15/2020Jefferies Financial GroupInitiated CoverageHold$44.00
5/8/2020Stifel NicolausLower TargetHold$55.00 ➝ $45.00
5/8/2020Piper SandlerLower TargetOverweight$62.00 ➝ $50.00
5/5/2020JPMorgan Chase & Co.Lower TargetNeutral$55.00 ➝ $40.00
(Data available from 4/30/2020 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 18 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/2/2024
  • 11 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2024
  • 28 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/1/2024
  • 22 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2024
  • 10 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/30/2025
  • 14 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/1/2025
  • 30 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2025
  • 23 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
4/30/2025

Current Sentiment

  • 23 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Glaukos logo
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More

Today's Range

Now: $93.61
Low: $92.82
High: $94.72

50 Day Range

MA: $99.73
Low: $81.84
High: $126.03

52 Week Range

Now: $93.61
Low: $77.91
High: $163.71

Volume

914,995 shs

Average Volume

645,850 shs

Market Capitalization

$5.34 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Glaukos?

The following sell-side analysts have issued stock ratings on Glaukos in the last year: BTIG Research, Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Piper Sandler, Stephens, Stifel Nicolaus, StockNews.com, Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for GKOS.

What is the current price target for Glaukos?

0 Wall Street analysts have set twelve-month price targets for Glaukos in the last year. Their average twelve-month price target is $156.17, suggesting a possible upside of 66.8%. UBS Group AG has the highest price target set, predicting GKOS will reach $182.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $120.00 for Glaukos in the next year.
View the latest price targets for GKOS.

What is the current consensus analyst rating for Glaukos?

Glaukos currently has 1 sell rating, 11 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GKOS.

What other companies compete with Glaukos?

Other companies that are similar to Glaukos include Zimmer Biomet, Smith & Nephew, Penumbra, Solventum and Stevanato Group. Learn More about companies similar to Glaukos.

How do I contact Glaukos' investor relations team?

Glaukos' physical mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier's listed phone number is (949) 367-9600 and its investor relations email address is [email protected]. The official website for Glaukos is www.glaukos.com. Learn More about contacing Glaukos investor relations.